Skip to main content
Erschienen in: Obesity Surgery 3/2012

01.03.2012 | Clinical Research

Early Improvement in Albuminuria in Non-diabetic Patients after Roux-en-Y Bariatric Surgery

verfasst von: Sumit Mohan, Jennifer Tan, Saritha Gorantla, Leaque Ahmed, Constance M. Park

Erschienen in: Obesity Surgery | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Obesity is a growing epidemic in the USA that has been shown to be associated with chronic kidney disease and albuminuria. Bariatric surgery is an effective means of achieving long-term weight loss and improvements in metabolic derangements including albumin excretion over the long term.

Methods

We report changes in urinary albumin excretion levels in the early post-operative period for a euglycemic, predominantly Hispanic American cohort undergoing Roux-en-Y gastric bypass surgery.

Results

Our cohort of 38 patients was largely female (89.5%) and predominantly Hispanic (76.3%) with a mean BMI of 46 ± 8.0 kg/m2. Over half (53.3%) of the patients with significant preoperative albumin excretion in our cohort lowered their albumin excretion levels to <20 mg/g of creatinine. This early reduction in albumin excretion in our cohort correlated significantly with the level of albumin excretion preoperatively but not with the degree of weight loss experienced in this early post-operative period.

Conclusions

Improvements in microalbuminuria in the early post-operative period after Roux-en-Y surgery may result from an interplay between changes in gastrointestinal hormones, insulin sensitivity, blood pressure, and adipose tissue—and needs further study.
Literatur
1.
Zurück zum Zitat Hsu C-y, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–8.PubMed Hsu C-y, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–8.PubMed
2.
Zurück zum Zitat Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.PubMedCrossRef Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.PubMedCrossRef
3.
Zurück zum Zitat Strengel B, Tarver-Carr M, Powe N, et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14:479–87. Strengel B, Tarver-Carr M, Powe N, et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14:479–87.
4.
Zurück zum Zitat Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55.PubMedCrossRef Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55.PubMedCrossRef
5.
Zurück zum Zitat Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:550–62.PubMedCrossRef Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:550–62.PubMedCrossRef
6.
Zurück zum Zitat Klausen KP, Parving HH, Scharling H, et al. Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol. 2009;71:40–5.CrossRef Klausen KP, Parving HH, Scharling H, et al. Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol. 2009;71:40–5.CrossRef
7.
Zurück zum Zitat Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Ren Physiol. 2008;294:F685–96.CrossRef Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Ren Physiol. 2008;294:F685–96.CrossRef
8.
Zurück zum Zitat Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis. 2001;37:720–7.PubMedCrossRef Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis. 2001;37:720–7.PubMedCrossRef
9.
Zurück zum Zitat Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.PubMedCrossRef Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.PubMedCrossRef
10.
Zurück zum Zitat Serra A, Romero R, Lopez D, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73:947–55.PubMedCrossRef Serra A, Romero R, Lopez D, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73:947–55.PubMedCrossRef
11.
Zurück zum Zitat Brantsma AH, Bakker SJL, de Zeeuw D, et al. Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol. 2006;17:331–5.PubMed Brantsma AH, Bakker SJL, de Zeeuw D, et al. Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol. 2006;17:331–5.PubMed
12.
Zurück zum Zitat Ferris M, Hogan SL, Chin H, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the add health wave III study. Clin J Am Soc Nephrol. 2007;2:1207–14.PubMedCrossRef Ferris M, Hogan SL, Chin H, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the add health wave III study. Clin J Am Soc Nephrol. 2007;2:1207–14.PubMedCrossRef
13.
Zurück zum Zitat Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.PubMedCrossRef Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.PubMedCrossRef
14.
Zurück zum Zitat Hillege HL, Janssen WMT, Bak A, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519–26.PubMedCrossRef Hillege HL, Janssen WMT, Bak A, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519–26.PubMedCrossRef
15.
Zurück zum Zitat Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian diabetes, obesity, and lifestyle study (AusDiab). Am J Kidney Dis. 2004;44:792–8.PubMed Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian diabetes, obesity, and lifestyle study (AusDiab). Am J Kidney Dis. 2004;44:792–8.PubMed
16.
Zurück zum Zitat Murtaugh MA, Jacobs Jr DR, Yu X, et al. Correlates of urinary albumin excretion in young adult blacks and whites: the coronary artery risk development in young adults study. Am J Epidemiol. 2003;158:676–86.PubMedCrossRef Murtaugh MA, Jacobs Jr DR, Yu X, et al. Correlates of urinary albumin excretion in young adult blacks and whites: the coronary artery risk development in young adults study. Am J Epidemiol. 2003;158:676–86.PubMedCrossRef
17.
Zurück zum Zitat Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 2009;76:145–8.PubMedCrossRef Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 2009;76:145–8.PubMedCrossRef
18.
Zurück zum Zitat de Zeeuw D, Parving H-H, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006;17:2100–5.PubMedCrossRef de Zeeuw D, Parving H-H, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006;17:2100–5.PubMedCrossRef
19.
Zurück zum Zitat Klausen KP, Parving HH, Scharling H, et al. Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol. 2009;71:40–5.CrossRef Klausen KP, Parving HH, Scharling H, et al. Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol. 2009;71:40–5.CrossRef
20.
Zurück zum Zitat Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among us adults, 1999–2000. JAMA. 2002;288:1723–7.PubMedCrossRef Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among us adults, 1999–2000. JAMA. 2002;288:1723–7.PubMedCrossRef
21.
Zurück zum Zitat Verhave JC, Hillege HL, Burgerhof JGM, et al. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol. 2003;14:1330–5.PubMedCrossRef Verhave JC, Hillege HL, Burgerhof JGM, et al. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol. 2003;14:1330–5.PubMedCrossRef
22.
Zurück zum Zitat Bello AK, de Zeeuw D, Nahas ME, et al. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant. 2007;22:1619–27.PubMedCrossRef Bello AK, de Zeeuw D, Nahas ME, et al. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant. 2007;22:1619–27.PubMedCrossRef
23.
Zurück zum Zitat Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRef Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRef
24.
Zurück zum Zitat Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med. 2001;134:1–11.PubMed Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med. 2001;134:1–11.PubMed
25.
Zurück zum Zitat Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27:2067–73.PubMedCrossRef Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27:2067–73.PubMedCrossRef
26.
Zurück zum Zitat Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–84.PubMedCrossRef Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–84.PubMedCrossRef
27.
Zurück zum Zitat Solerte S, Fioravanti M, Schifino N, et al. Effects of diet-therapy on urinary protein excretion albuminuria and renal hemodynamic function in obese diabetic patients with overt nephropathy. Int J Obes. 1989;13:203–11.PubMed Solerte S, Fioravanti M, Schifino N, et al. Effects of diet-therapy on urinary protein excretion albuminuria and renal hemodynamic function in obese diabetic patients with overt nephropathy. Int J Obes. 1989;13:203–11.PubMed
28.
Zurück zum Zitat Navarro-Diaz M, Serra A, Romero R, et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol. 2006;17:S213–7.PubMedCrossRef Navarro-Diaz M, Serra A, Romero R, et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol. 2006;17:S213–7.PubMedCrossRef
29.
Zurück zum Zitat Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol. 2003;14:1480–6.PubMedCrossRef Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol. 2003;14:1480–6.PubMedCrossRef
30.
Zurück zum Zitat Agrawal V, Khan I, Rai B, et al. The effect of weight loss after bariatric surgery on albuminuria. Clin Nephrol. 2008;70:194–202.PubMed Agrawal V, Khan I, Rai B, et al. The effect of weight loss after bariatric surgery on albuminuria. Clin Nephrol. 2008;70:194–202.PubMed
31.
Zurück zum Zitat Saiki A, Nagayama D, Ohhira M, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes Relat Metab Disord. 2005;29:1115–20.CrossRef Saiki A, Nagayama D, Ohhira M, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes Relat Metab Disord. 2005;29:1115–20.CrossRef
32.
Zurück zum Zitat Agrawal V, Krause KR, Chengelis DL, et al. Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis. 2009;5:20–6.PubMedCrossRef Agrawal V, Krause KR, Chengelis DL, et al. Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis. 2009;5:20–6.PubMedCrossRef
33.
Zurück zum Zitat Rubino FMD, Gagner MMDF, Gentileschi PMD, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236–42.PubMedCrossRef Rubino FMD, Gagner MMDF, Gentileschi PMD, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236–42.PubMedCrossRef
34.
Zurück zum Zitat Praga M. Obesity–a neglected culprit in renal disease. Nephrol Dial Transplant. 2002;17:1157–9.PubMedCrossRef Praga M. Obesity–a neglected culprit in renal disease. Nephrol Dial Transplant. 2002;17:1157–9.PubMedCrossRef
35.
Zurück zum Zitat de Jong P, Verhave J, Pinto-Sietsma S, et al. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord. 2002;26:S21–4.PubMedCrossRef de Jong P, Verhave J, Pinto-Sietsma S, et al. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord. 2002;26:S21–4.PubMedCrossRef
36.
Zurück zum Zitat Bosma R, van der Heide J, Oosterop E, et al. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int. 2004;65:259–65.PubMedCrossRef Bosma R, van der Heide J, Oosterop E, et al. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int. 2004;65:259–65.PubMedCrossRef
37.
Zurück zum Zitat Bomback AS, Klemmer P. Interaction of aldosterone and extracellularvolume in the pathogenesis of obesity associated kidney disease: a narrative review. Am J Nephrol. 2009;30:140–6.PubMedCrossRef Bomback AS, Klemmer P. Interaction of aldosterone and extracellularvolume in the pathogenesis of obesity associated kidney disease: a narrative review. Am J Nephrol. 2009;30:140–6.PubMedCrossRef
38.
Zurück zum Zitat Krikken J, Lely A, Bakker A, et al. The effect of teh a shift in sodium intake on renal hemodynamics is determined by body mass index in health young men. Kidney Int. 2007;71:260–5.PubMedCrossRef Krikken J, Lely A, Bakker A, et al. The effect of teh a shift in sodium intake on renal hemodynamics is determined by body mass index in health young men. Kidney Int. 2007;71:260–5.PubMedCrossRef
39.
Zurück zum Zitat Bigazzi R, Bianchi S, Bladari D, et al. Microalbuminuria in salt sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension. 1994;23:195–9.PubMed Bigazzi R, Bianchi S, Bladari D, et al. Microalbuminuria in salt sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension. 1994;23:195–9.PubMed
40.
Zurück zum Zitat Wolf G, Hamann A, Han D, et al. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int. 1999;56:860–72.PubMedCrossRef Wolf G, Hamann A, Han D, et al. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int. 1999;56:860–72.PubMedCrossRef
41.
Zurück zum Zitat Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645–56.PubMed Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645–56.PubMed
42.
Zurück zum Zitat Serra A, Granada ML, Romero R, et al. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr. 2006;25:400–8.PubMedCrossRef Serra A, Granada ML, Romero R, et al. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr. 2006;25:400–8.PubMedCrossRef
43.
Zurück zum Zitat Campos GM, Rabl C, Peeva S, et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg. 2010;14:15–23.PubMedCrossRef Campos GM, Rabl C, Peeva S, et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg. 2010;14:15–23.PubMedCrossRef
44.
Zurück zum Zitat De Simone G, Mancini M, Mainenti G, et al. Weight reduction lowers blood pressure independently of salt restriction. J Endocrinol Investig. 1992;15:339–43. De Simone G, Mancini M, Mainenti G, et al. Weight reduction lowers blood pressure independently of salt restriction. J Endocrinol Investig. 1992;15:339–43.
45.
Zurück zum Zitat Cutler JA. Randomized clinical trials of weight reduction in nonhypertensive persons. Ann Epidemiol. 1991;1:363–70.PubMedCrossRef Cutler JA. Randomized clinical trials of weight reduction in nonhypertensive persons. Ann Epidemiol. 1991;1:363–70.PubMedCrossRef
46.
Zurück zum Zitat Laferrere B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.PubMedCrossRef Laferrere B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.PubMedCrossRef
47.
Zurück zum Zitat Muscelli E, Mingrone G, Camastra S, et al. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med. 2005;118:51–7.PubMedCrossRef Muscelli E, Mingrone G, Camastra S, et al. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med. 2005;118:51–7.PubMedCrossRef
48.
Zurück zum Zitat Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252:966–71.PubMedCrossRef Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252:966–71.PubMedCrossRef
49.
Zurück zum Zitat Bose M, Oliván B, Teixeira J, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg. 2009;19:217–29.PubMedCrossRef Bose M, Oliván B, Teixeira J, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg. 2009;19:217–29.PubMedCrossRef
50.
Zurück zum Zitat Abu-Hamdah R, Rabiee A, Meneilly GS, et al. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94:1843–52.PubMedCrossRef Abu-Hamdah R, Rabiee A, Meneilly GS, et al. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94:1843–52.PubMedCrossRef
51.
Zurück zum Zitat Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21:1125–35.PubMedCrossRef Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21:1125–35.PubMedCrossRef
Metadaten
Titel
Early Improvement in Albuminuria in Non-diabetic Patients after Roux-en-Y Bariatric Surgery
verfasst von
Sumit Mohan
Jennifer Tan
Saritha Gorantla
Leaque Ahmed
Constance M. Park
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 3/2012
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0437-7

Weitere Artikel der Ausgabe 3/2012

Obesity Surgery 3/2012 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.